Industry-first AI layer built into the timveroOS Building Platform: cuts implementation to weeks and speeds every new ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...

NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...

Generic dapagliflozin is indicated for adults with type 2 diabetes and to reduce heart failure hospitalization risk in adults with T2D and established cardiovascular disease. The Food and Drug ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

Multiple dapagliflozin generic approvals are expected to intensify near-term market competition, requiring manufacturers to coordinate production readiness, launch timing, and labeling compliance ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.